Sintavers S.A. (manufacturer)

Ukraine

All drugs from this manufacturer

  • ONKO BCG 50 / ONKO BCG® 50 IMMUNOTHERAPEUTIC AGENT FOR PATIENTS WITH BLADDER CANCER

    The drug is used for the treatment of non-invasive forms of bladder cancer (papillary carcinoma, carcinoma in situ, tumor with spread to the subepithelial plate), as well as for the prevention of recurrences after surgical removal of the tumor.

    Dosage form: powder for oral suspension, for injection into the bladder

    Active substance Dosage
    live attenuated mycobacteria strain bacillus calmette-guerin brazilian substrain moreau 50 mg not less than 150 million CFU

    ATC: L03AX03